HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Cabanas, P Articles by Pombo, M Search for Related Content PubMed PubMed Citation Articles by Cabanas, P Articles by Pombo, M

Papillary thyroid carcinoma after recombinant GH therapy for Turner syndrome

¹ Pediatric Endocrinology, Growth and Adolescence Unit, Department of Pediatrics and ² Department of Morphological Sciences, Faculty of Medicine, Clinical University Hospital, University of Santiago de Compostela, Spain and ³ Pediatric Endocrinology Unit, Department of Pediatrics, Reina Sofía Clinical University Hospital, Córdoba, Spain

(Correspondence should be addressed to M Pombo; Email: pdmapoar{at}usc.es)

Abstract

Turner syndrome (TS) has been included for several years among the indications for GH treatment, generally with satisfactory outcomes. Nevertheless, the long-term effects of this treatment in non-GH deficient patients are not fully known. The incidence of thyroid carcinoma is rare in patients during childhood, it is unusual to find this neoplasia in children under sixteen years old. This article reports the cases of two Spanish patients with papillary thyroid carcinoma after GH treatment for TS. Recent studies have indicated a possible relationship between the GH–IGF axis and the pathogenesis of neoplasias, questioning the chance association of these two pathologies. In line with this, we detected GH receptor expression in the papillary carcinoma cells. Long-term prospective studies are required to clarify the possible effects of GH treatment on the risk of neoplasia.